Martin Witzenrath
Profile Url: martin-witzenrath
Researcher at Division of Pulmonary Inflammation, Chariteé - University Hospital Berlin
0
0
0
Cell, 2020-09-23
Video Abstract (AI generated)
Paper
Preprint
Cell
The emergence of SARS-CoV-2 led to pandemic spread of coronavirus disease 2019 (COVID-19), manifesting with respiratory symptoms and multi-organ dysfunction. Detailed characterization of virus-neutralizing antibodies and target epitopes is needed to understand COVID-19 pathophysiology and guide immunization strategies. Among 598 human monoclonal antibodies (mAbs) from ten COVID-19 patients, we identified 40 strongly neutralizing mAbs. The most potent mAb CV07-209 neutralized authentic SARS-CoV-2 with IC50 of 3.1 ng/ml. Crystal structures of two mAbs in complex with the SARS-CoV-2 receptor-binding domain at 2.55 and 2.70 A revealed a direct block of ACE2 attachment. Interestingly, some of the near-germline SARS-CoV-2 neutralizing mAbs reacted with mammalian self-antigens. Prophylactic and therapeutic application of CV07-209 protected hamsters from SARS-CoV-2 infection, weight loss and lung pathology. Our results show that non-self-reactive virus-neutralizing mAbs elicited during SARS-CoV-2 infection are a promising therapeutic strategy. ### Competing Interest Statement Related to this work the German Center for Neurodegenerative Diseases (DZNE) and the Charite - Universitaetsmedizin have filed a patent application on which JK, SMR, HCK, ESS, VMC, MAM, DW, LES and HP are named as inventors.